Areteia Therapeutics Inc.

Address: 101 Glen Lennox Drive Suite 300 Suite 3005

Sponsor Overview

assignment

Specializations

Eosinophilic Asthma

Areteia Therapeutics Inc. focuses on eosinophilic asthma, with clinical research centered on symptom control and reduction of disease burden in adolescents and adults.

Asthma exacerbation reduction
Pulmonary function
Adolescent and adult asthma care

The sponsor’s trial portfolio includes studies across multiple countries and research sites, reflecting a concentrated interest in respiratory disease management.

Severe Eosinophilic Asthma

A substantial part of the sponsor’s activity is directed toward severe eosinophilic asthma, a Type 2 inflammatory airway disease associated with frequent worsening and persistent respiratory impairment.

Severe asthma exacerbations
Long-term disease control
Respiratory symptom burden

Research in this area includes ongoing recruitment across a broad international network, indicating sustained attention to this high-need pulmonary condition.

Respiratory Function and Clinical Outcomes

The sponsor’s studies also emphasize pulmonary function and clinically meaningful outcomes relevant to daily breathing capacity and asthma stability.

Airflow and lung function
Exacerbation prevention
Functional respiratory improvement

This area aligns with the sponsor’s focus on measurable respiratory endpoints in people living with persistent eosinophilic airway disease.

Long-Term Safety and Maintenance Therapy

Areteia Therapeutics Inc. maintains interest in the long-term safety and continued use of therapies for participants with severe eosinophilic asthma.

Extended treatment follow-up
Safety monitoring
Chronic asthma management

This research area reflects attention to sustained treatment experience in a chronic respiratory population.

Sponsored Trials

Trial Name	Country	Status
Efficacy and Safety Evaluation of Dexpramipexole Dihydrochloride Monohydrate in Eosinophilic Asthma: A Randomized, Double-Blind, Placebo-Controlled Study	Poland Romania	Not Recruiting
Efficacy and Safety of Dexpramipexole in Severe Eosinophilic Asthma: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study	Bulgaria Poland Romania	Not Recruiting
Efficacy and Safety of Oral Dexpramipexole in Adolescents and Adults with Severe Eosinophilic Asthma: A Randomized, Double-Blind, Placebo-Controlled Study	Austria Croatia Czechia France Germany Hungary Italy Lithuania Spain	Not Recruiting
Long-Term Safety and Tolerability Assessment of Dexpramipexole in Severe Eosinophilic Asthma: An Open-Label Phase III Extension Study	Bulgaria Czechia Germany Italy Poland Romania Spain	Not Recruiting
Randomized, Double‑Blind, Placebo‑Controlled Trial of Oral Dexpramipexole (KNS‑760704) as Add‑On to Standard Inhaled Therapy in Adolescents and Adults with Severe Eosinophilic Asthma	Czechia	Not Yet Recruiting